Age Related Macular Degeneration Amd Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: age-related-macular-degeneration-amd
Age Related Macular Degeneration Amd Market — USD $8 Billion in 2023, Growing to USD 16.35null by 2033 at 7.2% CAGR
This report provides a comprehensive analysis of the Age Related Macular Degeneration (AMD) market, covering the market size, growth forecasts, industry trends, and regional insights for the period 2023-2033.
Key Takeaways
- Global market expands from $8.00 Billion in 2023 to $16.35 Billion in 2033 at a 7.2% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe and Asia Pacific show substantial increases: Europe from $2.37 Billion to $4.84 Billion; Asia Pacific from $1.47 Billion to $3.00 Billion.
- Leading companies include Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, and Alcon Inc.
- Market growth supported by aging populations, improved diagnostics, rising awareness, and ongoing therapeutic R&D.
Age Related Macular Degeneration Amd Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This market report examines the Age Related Macular Degeneration sector from 2023 to 2033, documenting an increase from $8.00 Billion to $16.35 Billion and a 7.2% CAGR. Demand is driven by demographic shifts toward older populations, heightened attention to ocular health, advances in diagnostic methods, and intensified pharmaceutical and surgical development. Regional data reveal notable expansion across North America, Europe, and Asia Pacific, with North America holding the largest market by 2033. The analysis covers segmentation by disease type, treatment approach, disease stage, and distribution channel, and profiles key players such as Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, and Alcon Inc. The report highlights industry dynamics including increased R&D investment, emergence of novel therapies, and challenges related to treatment costs and awareness. Strategic insights are provided to inform stakeholders, healthcare providers, and investors considering opportunities across product, clinical, and geographic segments.
Key Growth Drivers
- Rising elderly population increasing prevalence and demand for AMD management.
- Improved diagnostic technologies enabling earlier detection and treatment initiation.
- Ongoing pharmaceutical and surgical research expanding therapy options and pipeline activity.
- Greater public awareness and screening initiatives improving diagnosis rates and treatment uptake.
- Increased investment by leading companies supporting product development and market penetration.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.00 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $16.35 Billion |
| Top Companies | Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, Alcon Inc. |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Age Related Macular Degeneration Amd Market Overview
Customize Age Related Macular Degeneration Amd Market Report market research report
- ✔ Get in-depth analysis of Age Related Macular Degeneration Amd market size, growth, and forecasts.
- ✔ Understand Age Related Macular Degeneration Amd's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Age Related Macular Degeneration Amd
What is the Market Size & CAGR of Age Related Macular Degeneration Amd Market Report market in 2023?
Age Related Macular Degeneration Amd Industry Analysis
Age Related Macular Degeneration Amd Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Age Related Macular Degeneration Amd Market Report Market Analysis Report by Region
Europe Age Related Macular Degeneration Amd Market Report:
Europe grows from $2.37 Billion in 2023 to $4.84 Billion in 2033. This progression is associated with demographic ageing, enhanced screening and diagnostic capabilities, and investments in therapeutic development that support higher treatment uptake.Asia Pacific Age Related Macular Degeneration Amd Market Report:
Asia Pacific grows from $1.47 Billion in 2023 to $3 Billion in 2033. Growth drivers include rising awareness of ocular health, expanding access to diagnostics and care, and growing clinical and commercial interest in the region.North America Age Related Macular Degeneration Amd Market Report:
North America is largest regional market, rising from $2.99 Billion in 2023 to $6.11 Billion in 2033. Regional expansion is linked to an ageing population, strong healthcare infrastructure, high levels of diagnostic adoption, and active R&D and commercial activity by major companies.South America Age Related Macular Degeneration Amd Market Report:
Latin America grows from $0.28 Billion in 2023 to $0.57 Billion in 2033. Regional momentum is tied to improving healthcare access, increased awareness of AMD, and gradual uptake of available treatments and diagnostic services.Middle East & Africa Age Related Macular Degeneration Amd Market Report:
Middle East and Africa grows from $0.9 Billion in 2023 to $1.83 Billion in 2033. Increased attention to eye health, growing diagnostic capacity, and expanding clinical services support market growth in this region.Tell us your focus area and get a customized research report.
Research Methodology
Age Related Macular Degeneration Amd Market Analysis By Disease Type
The AMD market segmentation by disease type highlights Dry AMD commanding a significant market share with a size of $6.54 billion in 2023, expected to grow to $13.37 billion by 2033, holding steady at 81.78% market share. Wet AMD, while smaller, is projected to grow from $1.46 billion to $2.98 billion, maintaining an 18.22% share.
Age Related Macular Degeneration Amd Market Analysis By Treatment Type
Pharmaceuticals represent the largest share in treatment types, valued at $5.36 billion in 2023, expected to reach $10.95 billion by 2033 with a 66.97% market share. Surgical procedures and nutritional supplements are also crucial, with sizes expected to grow from $1.67 billion to $3.41 billion and $0.98 billion to $2.00 billion, respectively.
Age Related Macular Degeneration Amd Market Analysis By Distribution Channel
The distribution channel segment indicates that Hospital Pharmacies hold a significant market share of $5.36 billion in 2023 and is projected to double to $10.95 billion by 2033. Retail and online pharmacies follow, with estimated values growing considerably within the same period.
Age Related Macular Degeneration Amd Market Analysis By Stage Of Disease
The segmentation by disease stage reveals that the Early Stage holds a substantial market size of $5.36 billion in 2023, anticipated to grow to $10.95 billion. The Intermediate and Advanced Stages are also growing segments, driven by the increasing prevalence of AMD.
Age Related Macular Degeneration Amd Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Age Related Macular Degeneration Amd Industry
Regeneron Pharmaceuticals, Inc.:
A leading player in the AMD market known for its innovative treatments and high-quality research, particularly in developing drug therapies for Wet AMD.Novartis AG:
A global healthcare leader that offers a range of treatments for AMD and is heavily involved in research, focused on improving patient outcomes through innovative therapies.Roche Holdings AG:
Notable for its significant contributions towards advancing AMD treatment solutions, Roche emphasizes precision medicine in its offerings.Bayer AG:
Bayer is recognized for its extensive range of products related to eye diseases, especially for its commitment to research and development in AMD treatments.Alcon Inc.:
A global leader in eye care, Alcon provides a range of surgical and pharmaceutical products targeting AMD, committed to enhancing patient care.We're grateful to work with incredible clients.
FAQs
What is the market size of the AMD market in 2023?
The market size in 2023 is $8.00 Billion as reported for the Age Related Macular Degeneration market.
How big will the AMD market be in 2033?
By 2033 the market is projected to reach $16.35 Billion according to the provided forecast data.
What is CAGR for the forecast period?
The reported compound annual growth rate for the 2023 to 2033 forecast period is 7.2%.
Is there a single fastest Growing region in the Age Related Macular Degeneration Amd Market Report market?
No single fastest-growing region is stated for the Age Related Macular Degeneration Amd Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies lead the AMD market?
Top listed companies include Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, and Alcon Inc.
What are primary treatment categories in the market?
Treatment categories specified include Pharmaceuticals, Surgical Procedures, and Nutritional Supplements as key approaches.
How are market segments defined by disease stage?
Disease stage segmentation includes Early Stage, Intermediate Stage, and Advanced Stage as the principal categories.
What distribution channels are highlighted?
Distribution channels mentioned are Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies across the market.
What drives regional growth in Europe?
Europe’s expansion, from $2.37 Billion in 2023 to $4.84 Billion in 2033, is linked to aging demographics, improved diagnostics, and therapeutic development.
Who contributes to industry innovation?
Leading pharmaceutical and medical device firms such as Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, and Alcon Inc. drive innovation and pipeline activity.